Monte Rosa Therapeutics, Inc.GLUE
Price (close)
$11.72
Market cap
$999.9M
P/E
—
Revenue (TTM)
$28.7M
Net income
-$161.1M
Dividend yield
—
1-year total return
78.9%
Net margin
-560.8%
Revenue growth
-83.9%
Debt / equity
—
What Monte Rosa Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $75.6M | $123.7M |
| Net income | -$35.9M | -$74.0M | -$108.5M | -$135.4M | -$72.7M | -$38.6M |
| Free cash flow | -$26.4M | -$69.1M | -$105.4M | -$62.8M | $38.0M | -$27.5M |
More on GLUE.
- Monte Rosa Therapeutics, Inc. summary
- Monte Rosa Therapeutics, Inc. financial statements
- Monte Rosa Therapeutics, Inc. key metrics
- Monte Rosa Therapeutics, Inc. health scores and style box
- Monte Rosa Therapeutics, Inc. earnings
- Monte Rosa Therapeutics, Inc. dividends
- Monte Rosa Therapeutics, Inc. valuation
- Monte Rosa Therapeutics, Inc. ownership and insiders
- Monte Rosa Therapeutics, Inc. peers
Figures from Monte Rosa Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.